PYXS 10-Q: SEC filing
Pyxis Oncology
Filed with the SEC on · accession 0001193125-26-448612
PYXS filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -3.0% by the first close after the filing.
Summary of the filing
Pyxis Oncology filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from license agreements and a subsequent underwritten public offering in October 2026.
Key details
How PYXS stock reacted
Close before
$1.66
Nov 4, 2026
First close after
-3.01%
$1.61
5 trading days
—
Since filing
+0.00%
$1.66
✦ Ask GOAX AI about this filing — what it means for PYXS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PYXS?
Click hereFrequently asked questions
What did PYXS file with the SEC on Nov 5, 2026?
PYXS filed a 10-Q (SEC filing). Pyxis Oncology filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue from license agreements and a subsequent underwritten public offering in October 2026.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did PYXS stock react to this filing?
PYXS closed at $1.66 before the filing and $1.61 on Nov 5, 2026 (-3.01%).
Other PYXS SEC filings
- 8-K · SEC filingNov 5, 2026
- SCHEDULE 13G/A · SEC filingNov 3, 2026
- DEF 14A · SEC filingOct 21, 2026
- SCHEDULE 13G/A · SEC filingOct 9, 2026
- SCHEDULE 13G · SEC filingOct 5, 2026
- SCHEDULE 13G/A · SEC filingOct 2, 2026
- 424B5 · Secondary offeringOct 1, 2026
- 8-K · Secondary offeringOct 1, 2026
- 8-K · Fda approvalSep 9, 2026
- 8-K · Ceo changeSep 8, 2026
Get alerts when PYXS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days